Restoration of retinoid sensitivity by MDR1 ribozymes in retinoic acid- resistant myeloid leukemic cells

Blood

Volumn 91, Issue 7, 1998, Pages 2452-2458

  Matsushita, Hiromichi ^b   Kizaki, Masahiro ^a   Kobayashi, Hiroyuki ^b   Ueno, Hironori ^b   Muto, Akihiro ^b   Takayama, Nobuyuki ^b   Awaya, Norihiro ^b   Kinjo, Kentaro ^b   Hattori, Yutaka ^b   Ikeda, Yasuo ^b  

^a KEIO UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RETINOIC ACID; RIBOZYME;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CELL PROLIFERATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0032055522     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.7.2452     Document Type: Article

References (38)

1. Lotan R: Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochem Biophys Acta 605:33, 1980
2. Sporn MB, Roberts AB: Role of retinoids in differentiation and carcinogenesis. Cancer Res 43:3034, 1983
3. Breitman TR, Selonick SE, Collins SJ: Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77:2936, 1980
4. Koeffler HP: Induction of differentiation of human acute myelogenous leukemia cells: Therapeutic implications. Blood 62:709, 1983
5. Kizaki M, Ikeda Y, Tanosaki R, Nakajima H, Morikawa M, Sakashita A, Koeffler HP: Effects of novel retinoic acid compound, 9-cis-retinoic acid, on proliferation, differentiation, and expression of retinoic acid receptor-α and retinoid X receptor-α RNA by HL-60 cells. Blood 82:3592, 1993
6. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu HT, Wang ZY: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567, 1988
7. Castaigne S, Chomienne C, Daniel MT, Ballarini P, Berger R, Fenaux P, Degos L: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704, 1990
8. Warrell RP Jr, Frankel SR, Miller WH Jr, Sheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovski E: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324:1385, 1991
9. Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K, Hiraoka H, Yamada O, Oh H, Saito K, Matsuda S, Minato K, Ueda T, Ohno R: All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 85:1202, 1995
10. Warrell RP Jr, de The H, Wang ZY, Degos L: Acute promyelocytic leukemia. N Engl J Med 329:177, 1993
11. Kizaki M, Ueno H, Yamazoe Y, Shimada M, Takayama N, Muto A, Matsushita H, Nakajima H, Morikawa M, Koeffler HP, Ikeda Y: Mechanisms of retinoid resistance: Possible role of cytochrome P450 and P-glycoprotein. Blood 87:725, 1996
12. Chen C, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug resistant human cells. Cell 47:381, 1986
13. Hamada H, Tsuruo T: Functional role for the 170-to 180-kDa glycoprotein specific to drug-resistant timor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 83:7785, 1986
14. Uhlenbeck OC: A small catalytic oligoribonucleotide. Nature 328:696-600, 1987
15. Cech TR: Ribozymes and their medical implications. JAMA 260:3030, 1988
16. Haseloff J, Gerlach WJ: Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334:585, 1988
17. Kobayashi H, Dorai T, Holland JF, Ohnuma T: Cleavage of human MDR1 mRNA by a hammerhead ribozyme. FEBS Lett 319:71, 1993
18. Kobayashi H, Dorai T, Holland JF, Ohnuma T: Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res 54:1271, 1994
19. Gallagher RE, Bilello PA, Ferrari AC, Chang CS, Yen RWC, Nickols WA, Muly EM III: Characterization of differentiation inducer-resistant HL-60 cells. Leuk Res 9:961, 1985
20. Arkin H, Ohnuma T, Kamen BA, Holland JF, Vollabhajosula S: Multidrug resistance in human leukemia cell line selected for resistance to trimetrexate. Cancer Res 49:6556, 1989
21. Gunning P, Leavitt J, Muscat G, Ng S-Y, Kedes L: A human β-actin expression vector system directs high accumulation of antisense transcript. Proc Natl Acad Sci USA 84:4831, 1987
22. Ponte P, Ng S-Y, Engel J, Gunning P, Kedes L: Evolutionary conservation in the untranslated regions of actin mRNA: DNA sequence of human beta-actin cDNA. Nucleic Acids Res 12:1687, 1984
23. Kizaki M, Nakajima H, Mori S, Koike T, Morikawa M, Ohta M, Saito M, Koeffler HP, Ikeda Y: Novel retinoic acid, 9-cis retinoic acid, in combination with all-trans retinoic acid is an effective inducer of differentiation of retinoic acid-resistant HL-60 cells. Blood 83:3289, 1994
24. Muindi JF, Frankel SR, Miller WH Jr, Jakubowski A, Scheinberg DA, Young CW, Dmitrovski E, Warrell RP Jr: Continuous treatment with all-trans retinoic acid and causes a progressive decrease in plasma concentrations: Implications for relapse and "resistance" in acute promyelocytic leukemia. Blood 79:299, 1992
25. Warrell RP Jr: Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies, and implications. Blood 82: 1949, 1993
26. Paietta E, Andersen J, Racevski J, Gallagher R, Bennett J, Yunis J, Cassileth P, Wiernik PH: Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: Immunological, molecular and functional analyses. Leukemia 8:968, 1994
27. Drach D, Zhao S, Drach J, Andreeff M: Low incidence of MDR1 expression in acute promyelocytic leukemia. Br J Haematol 90:369, 1995
28. Sarver N, Cantin EM, Chang PS, Zaia JA, Lande PA, Stephens DA, Rossi JJ: Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247:1222, 1990
29. Scanlon KJ, Jiao L, Funato T, Wang W, Tone T, Rossi JJ, Kashani-Saket M: Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA 88:10591, 1991
30. Homann M, Tzortzakaki S, Ritter K, Sczakiel G, Tabler M: Incorporation of the catalytic domain of a hammerhead ribozyme into antisense RNA enhances its inhibitory effect on the replication of human immunodeficiency virus type I. Nucleic Acids Res 21:2809, 1993
31. Snyder DS, Wu Y, Wang JL, Rossi JJ, Swiderski P, Kaplan BE, Forman SJ: Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood 82:600, 1993
32. Kearney P, Wright LA, Milliken S, Biggs JC: Improved specificity of ribozyme-mediated cleavage of bcr-abl mRNA. Exp Hematol 23:986, 1995
33. Leopold LH, Shore SK, Newkirk TA, Reddy RMV, Reddy P: Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood 85:2162, 1995
34. Pace U, Bockman JM, MacKay BJ, Miller WH Jr, Dmitrovsky E: A ribozyme which discriminates in vitro between PML/RARα, the t(15;17)-associated fusion RNA of acute promyelocytic leukemia, and PML and RARα, the transcripts from the norearranged alleles. Cancer Res 54:6365, 1994
35. Matsushita H, Kobayashi H, Mori S, Kizaki M, Ikeda Y: Ribozymes cleave the AML1/MTG8 fusion transcript and inhibit proliferation of leukemic cells with t(8;21). Biochem Biophys Res Commun 215:431, 1995
36. Kiehntopf M, Esquivel EL, Brach MA, Herrmann F: Clinical application of ribozymes. Lancet 345:1027, 1995
37. Robertson KA, Emai B, Collins SJ: Retinoic acid-resistant HL-60 cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood 80:1885, 1992
38. Li YP, Said F, Gallagher RE: Retinoic acid-resistant HL-60 cells exclusively contain mutant retinoic acid receptor-α. Blood 83:3298, 1994